CA2938791A1 - Fgf-18 compound dosing regimen - Google Patents
Fgf-18 compound dosing regimen Download PDFInfo
- Publication number
- CA2938791A1 CA2938791A1 CA2938791A CA2938791A CA2938791A1 CA 2938791 A1 CA2938791 A1 CA 2938791A1 CA 2938791 A CA2938791 A CA 2938791A CA 2938791 A CA2938791 A CA 2938791A CA 2938791 A1 CA2938791 A1 CA 2938791A1
- Authority
- CA
- Canada
- Prior art keywords
- fgf
- compound
- cartilage
- weeks
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14000600.8 | 2014-02-20 | ||
| EP14000600 | 2014-02-20 | ||
| PCT/EP2015/053624 WO2015124727A1 (en) | 2014-02-20 | 2015-02-20 | Fgf-18 compound dosing regimen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2938791A1 true CA2938791A1 (en) | 2015-08-27 |
Family
ID=50151088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2938791A Abandoned CA2938791A1 (en) | 2014-02-20 | 2015-02-20 | Fgf-18 compound dosing regimen |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9724388B2 (OSRAM) |
| EP (2) | EP3107559B1 (OSRAM) |
| JP (2) | JP6431083B2 (OSRAM) |
| KR (2) | KR102410986B1 (OSRAM) |
| CN (2) | CN106456713A (OSRAM) |
| AR (2) | AR099558A1 (OSRAM) |
| AU (2) | AU2015220777B2 (OSRAM) |
| BR (2) | BR112016018685A2 (OSRAM) |
| CA (1) | CA2938791A1 (OSRAM) |
| DK (2) | DK3119417T3 (OSRAM) |
| ES (2) | ES2689071T3 (OSRAM) |
| HR (2) | HRP20181572T1 (OSRAM) |
| HU (1) | HUE040350T2 (OSRAM) |
| IL (2) | IL247083B (OSRAM) |
| LT (2) | LT3107559T (OSRAM) |
| MX (2) | MX2016010872A (OSRAM) |
| NZ (1) | NZ723148A (OSRAM) |
| PL (2) | PL3119417T3 (OSRAM) |
| PT (2) | PT3119417T (OSRAM) |
| RS (2) | RS57853B1 (OSRAM) |
| RU (2) | RU2700582C2 (OSRAM) |
| SG (2) | SG11201606505UA (OSRAM) |
| SI (2) | SI3107559T1 (OSRAM) |
| WO (2) | WO2015124731A1 (OSRAM) |
| ZA (2) | ZA201605547B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20181573T1 (hr) | 2014-02-20 | 2018-11-30 | Merck Patent Gmbh | Implantat koji sadrži fgf-18 |
| JP6431083B2 (ja) | 2014-02-20 | 2018-11-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８化合物の投与計画 |
| CA2971315C (en) | 2015-01-29 | 2023-02-14 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| ES2878575T3 (es) | 2016-02-22 | 2021-11-19 | Novartis Ag | Métodos para usar agonistas del FXR |
| DK3687558T3 (da) | 2017-09-29 | 2022-06-20 | Merck Patent Gmbh | Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse |
| DK3688468T3 (da) * | 2017-09-29 | 2022-06-20 | Merck Patent Gmbh | Inflammatoriske biomarkører til forudsigelse af modtageligheden for fgf-18 forbindelse |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
| AU2020218844A1 (en) * | 2019-02-08 | 2021-08-19 | Merck Patent Gmbh | Treatment of patients at risk of rapid progression of osteoarthritis |
| KR102920449B1 (ko) * | 2023-03-29 | 2026-02-03 | 주식회사 아이프로테인테라퓨틱스 | 인터류킨-1 수용체 길항제 변이체 및 이의 용도 |
| WO2025077768A1 (en) * | 2023-10-11 | 2025-04-17 | Sichuan Real & Best Biotech Co., Ltd. | Compositions and methods for treating arthritis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136970A1 (en) * | 2002-10-07 | 2004-07-15 | Ellsworth Jeff L. | Methods for administering FGF18 |
| ES2706848T3 (es) | 2004-07-06 | 2019-04-01 | Zymogenetics Inc | Composición farmacéutica que comprende FGF18 y antagonista de IL-1 y método de uso |
| AU2006326870A1 (en) * | 2005-12-22 | 2007-06-28 | Apollo Life Sciences | Transdermal delivery of pharmaceutical agents |
| MY148277A (en) * | 2006-08-25 | 2013-03-29 | Ares Trading Sa | Treatment of cartilage disorders with fgf-18 |
| KR101419961B1 (ko) | 2006-08-25 | 2014-07-30 | 아레스 트레이딩 에스.에이. | Ｆｇｆ-18 로 연골 질환의 치료 |
| DE102006043260A1 (de) * | 2006-09-11 | 2008-03-27 | Krones Ag | Etikettieranlage |
| CN103547580B (zh) * | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
| BR112016018704B1 (pt) | 2014-02-20 | 2021-01-05 | Merck Patent Gmbh | processo para produção de um material de cartilagem transplantável para engenharia de tecido |
| HRP20181573T1 (hr) | 2014-02-20 | 2018-11-30 | Merck Patent Gmbh | Implantat koji sadrži fgf-18 |
| JP6431083B2 (ja) | 2014-02-20 | 2018-11-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８化合物の投与計画 |
-
2015
- 2015-02-20 JP JP2016553329A patent/JP6431083B2/ja active Active
- 2015-02-20 EP EP15706006.2A patent/EP3107559B1/en active Active
- 2015-02-20 ES ES15706006.2T patent/ES2689071T3/es active Active
- 2015-02-20 US US15/120,134 patent/US9724388B2/en active Active
- 2015-02-20 DK DK15707076.4T patent/DK3119417T3/en active
- 2015-02-20 SG SG11201606505UA patent/SG11201606505UA/en unknown
- 2015-02-20 NZ NZ723148A patent/NZ723148A/en unknown
- 2015-02-20 EP EP15707076.4A patent/EP3119417B1/en active Active
- 2015-02-20 SI SI201530428T patent/SI3107559T1/sl unknown
- 2015-02-20 JP JP2016553284A patent/JP6431082B2/ja active Active
- 2015-02-20 PL PL15707076T patent/PL3119417T3/pl unknown
- 2015-02-20 RU RU2016137292A patent/RU2700582C2/ru active
- 2015-02-20 PL PL15706006T patent/PL3107559T3/pl unknown
- 2015-02-20 AR ARP150100507A patent/AR099558A1/es unknown
- 2015-02-20 RS RS20181167A patent/RS57853B1/sr unknown
- 2015-02-20 DK DK15706006.2T patent/DK3107559T3/en active
- 2015-02-20 HU HUE15706006A patent/HUE040350T2/hu unknown
- 2015-02-20 CA CA2938791A patent/CA2938791A1/en not_active Abandoned
- 2015-02-20 LT LTEP15706006.2T patent/LT3107559T/lt unknown
- 2015-02-20 SG SG11201606502YA patent/SG11201606502YA/en unknown
- 2015-02-20 WO PCT/EP2015/053631 patent/WO2015124731A1/en not_active Ceased
- 2015-02-20 AR ARP150100508A patent/AR099510A1/es unknown
- 2015-02-20 MX MX2016010872A patent/MX2016010872A/es active IP Right Grant
- 2015-02-20 KR KR1020167025246A patent/KR102410986B1/ko active Active
- 2015-02-20 MX MX2016010871A patent/MX2016010871A/es active IP Right Grant
- 2015-02-20 LT LTEP15707076.4T patent/LT3119417T/lt unknown
- 2015-02-20 SI SI201530410T patent/SI3119417T1/sl unknown
- 2015-02-20 RU RU2016137289A patent/RU2691946C2/ru active
- 2015-02-20 US US15/120,131 patent/US9889179B2/en active Active
- 2015-02-20 ES ES15707076.4T patent/ES2688551T3/es active Active
- 2015-02-20 PT PT15707076T patent/PT3119417T/pt unknown
- 2015-02-20 BR BR112016018685A patent/BR112016018685A2/pt not_active Application Discontinuation
- 2015-02-20 BR BR112016018696A patent/BR112016018696A2/pt not_active Application Discontinuation
- 2015-02-20 HR HRP20181572TT patent/HRP20181572T1/hr unknown
- 2015-02-20 AU AU2015220777A patent/AU2015220777B2/en active Active
- 2015-02-20 RS RS20181168A patent/RS57709B1/sr unknown
- 2015-02-20 AU AU2015220773A patent/AU2015220773B2/en active Active
- 2015-02-20 PT PT15706006T patent/PT3107559T/pt unknown
- 2015-02-20 CN CN201580020532.4A patent/CN106456713A/zh active Pending
- 2015-02-20 WO PCT/EP2015/053624 patent/WO2015124727A1/en not_active Ceased
- 2015-02-20 HR HRP20181570TT patent/HRP20181570T1/hr unknown
- 2015-02-20 KR KR1020167025245A patent/KR102410988B1/ko active Active
- 2015-02-20 CN CN201580020536.2A patent/CN106232622A/zh active Pending
-
2016
- 2016-08-03 IL IL247083A patent/IL247083B/en active IP Right Grant
- 2016-08-03 IL IL247084A patent/IL247084B/en active IP Right Grant
- 2016-08-10 ZA ZA2016/05547A patent/ZA201605547B/en unknown
- 2016-08-10 ZA ZA2016/05548A patent/ZA201605548B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015220773B2 (en) | FGF-18 compound dosing regimen | |
| KR101419961B1 (ko) | Ｆｇｆ-18 로 연골 질환의 치료 | |
| CN101505787B (zh) | 软骨障碍的治疗 | |
| CA2938793C (en) | Fgf-18 compound dosing regimen | |
| RU2745453C2 (ru) | Комбинированная композиция, содержащая соединение fgf-18 | |
| HK1231895A1 (en) | Fgf-18 compound dosing regimen | |
| HK1231754A1 (zh) | Fgf-18化合物给药方案 | |
| HK1129852B (en) | Treatment of cartilage disorders | |
| HK1129852A (en) | Treatment of cartilage disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200130 |
|
| FZDE | Discontinued |
Effective date: 20230802 |